Test Code SHPV Human Papillomavirus (HPV) DNA Detection with Genotyping, High-Risk Types by PCR, SurePath, Varies
Useful For
Detection of high-risk (HR) genotypes associated with the development of cervical cancer
An aid in triaging women with abnormal Pap smear test results
Individual genotyping of human papillomavirus (HPV)-16 and/or HPV-18, if present
Reporting Name
HPV with Genotyping, PCR, SurepathSpecimen Type
VariesNecessary Information
Specimen source, collection date, and patient identifiers are required.
Specimen Required
Supplies: Cobas PCR Media Tube w/Cap (T945)
Specimen Type: Cervical (endocervical or ectocervical) or vaginal
Specimen Volume: 3.0 mL
Collection Instructions:
1. Aliquot 3 mL SurePath specimen into Cobas PCR Media Tube w/Cap tube.
2. Bag specimens individually as they have a tendency to leak during transport.
3. Place labels on the vial and on the bag.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | 42 days | |
Refrigerated | 42 days |
Reference Values
Negative for HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
Interpretation
A positive result indicates the presence of human papillomavirus (HPV) DNA from one or more of the following genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
For patients with atypical squamous cells of undetermined significance Pap smear test result and who are positive for high-risk (HR) HPV, consider referral for colposcopy, if clinically indicated.
A negative result indicates the absence of HPV DNA of the targeted genotypes.
For women aged 30 years and older with a negative Pap smear test result but who are positive for HPV-16 and/or HPV-18, consider referral for colposcopy, if clinically indicated.
For women aged 30 years and older with a negative Pap smear test result, positive HR HPV test result, but who are negative for HPV-16 and HPV-18, consider repeat testing by both cytology and a HR HPV test in 12 months.
Day(s) Performed
Monday through Saturday
Report Available
3 to 6 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87624
G0476 (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
SHPV | HPV with Genotyping, PCR, Surepath | 77378-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
SS018 | Specimen Source | 31208-2 |
36003 | HPV High Risk type 16, PCR | 61372-9 |
36004 | HPV High Risk type 18, PCR | 61373-7 |
36005 | HPV other High Risk types, PCR | 77375-4 |
Clinical Reference
1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204. doi: 10.1097/LGT.0b013e31824ca9d5Â Â
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. doi:10.1002/(SICI)1096-9896(199909)189:1
3. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056. doi:10.1016/S1470-2045(10)70230-8
4. Wright TC Jr, Stoler MH, Sharma A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV positive, cytology-negative results. Am J Clin Pathol. 2011;136(4):578-586. doi:10.1309/AJCPTUS5EXAS6DKZ
Method Name
Real-Time Polymerase Chain Reaction (PCR)
Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.